Sunshine Biopharma(SBFM) - 2025 Q1 - Quarterly Results

Financial Performance - Sunshine Biopharma Inc. reported financial results for the fiscal year ended December 31, 2024[5] - The company announced a revenue increase of 25% year-over-year, reaching $10 million[5] - Net loss for the fiscal year was reported at $2 million, a reduction from $3 million in the previous year, indicating improved financial health[5] - The company provided guidance for 2025, projecting revenue growth of 40% to $14 million[5] User Growth - User data showed a growth in active users by 30%, totaling 150,000 users by the end of 2024[5] Product Development - The company plans to launch two new products in Q3 2025, aiming to capture additional market share[5] - Sunshine Biopharma is exploring potential acquisitions to expand its product portfolio and market presence[5] - Research and development expenses increased by 15%, reflecting ongoing investment in new technologies[5] Market Expansion - The company is focusing on expanding its market reach in Europe and Asia, targeting a 20% increase in international sales[5] - Sunshine Biopharma is implementing new marketing strategies to enhance brand visibility and customer engagement[5]